|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003873,
umls-concept:C0005522,
umls-concept:C0021311,
umls-concept:C0030705,
umls-concept:C0035452,
umls-concept:C0178719,
umls-concept:C0281481,
umls-concept:C0332257,
umls-concept:C0521009,
umls-concept:C0596227,
umls-concept:C1274040,
umls-concept:C1578536
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2006-8-28
|
|
pubmed:abstractText |
To determine whether the rate of serious infection is higher in anti-tumor necrosis factor (anti-TNF)-treated rheumatoid arthritis (RA) patients compared with RA patients treated with traditional disease-modifying antirheumatic drugs (DMARDs).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antirheumatic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Immunologic Factors,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Tumor Necrosis Factor,
http://linkedlifedata.com/resource/pubmed/chemical/TNFR-Fc fusion protein,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/adalimumab,
http://linkedlifedata.com/resource/pubmed/chemical/infliximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0004-3591
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
54
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2368-76
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16868999-Antibodies, Monoclonal,
pubmed-meshheading:16868999-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:16868999-Antirheumatic Agents,
pubmed-meshheading:16868999-Arthritis, Rheumatoid,
pubmed-meshheading:16868999-Bacterial Infections,
pubmed-meshheading:16868999-Cohort Studies,
pubmed-meshheading:16868999-Disease Notification,
pubmed-meshheading:16868999-Female,
pubmed-meshheading:16868999-Great Britain,
pubmed-meshheading:16868999-Humans,
pubmed-meshheading:16868999-Immunocompromised Host,
pubmed-meshheading:16868999-Immunoglobulin G,
pubmed-meshheading:16868999-Immunologic Factors,
pubmed-meshheading:16868999-Male,
pubmed-meshheading:16868999-Middle Aged,
pubmed-meshheading:16868999-Prospective Studies,
pubmed-meshheading:16868999-Receptors, Tumor Necrosis Factor,
pubmed-meshheading:16868999-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
|
|
pubmed:affiliation |
British Society for Rheumatology Biologics Register Control Centre Consortium, Manchester, UK.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
